Skip to content

Author

H. Veelken

We have 1 of 12 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Long-term outcome of a DLI-based treatment strategy in patients with relapsed AML after TCD allogeneic stem cell transplantation is hampered by GvHD and late relapse.

The 5-year overall survival of a DLI-based strategy can induce durable remission in patients with low-burden morphologic AML relapse after TCD alloSCT, even without prior cytoreduction.

J. Bergsma, E. Argiro, K. Oosterink et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.